Search clinical trials for: cain457f

Total 36 results

Novartis Pharmaceuticals

Not yet recruiting

Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis (Toddler)

Juvenile Idiopathic Arthritis
Novartis Pharmaceuticals

Recruiting

A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. (NEPTUNUS-Ext)

Sjogrens Syndrome

United States, Spain, Austria, Belgium, Japan, Germany, Turkey, Hungary, Israel, Taiwan, Italy, France, Colombia, Argentina, Portugal, Sweden, Australia, Slovakia, United Kingdom, Guatemala, Brazil, Czechia, Poland, Bulgaria, Canada, Lith... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy (UnchAIN)

Tendinopathy

Germany
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome (TWINSS Extn)

Sjogren's Syndrome

United Kingdom, Netherlands, Australia, Austria, Israel, France, Germany, Greece, Hungary, Italy, United States, Korea, Republic of, Japan, Portugal, Russian Federation, Turkey, Colombia, Romania, Argentina, Chile, Brazil, Canada, S...
Novartis Pharmaceuticals

Active, not recruiting

Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment (AgAIN)

Psoriatic Arthritis

Germany
Novartis Pharmaceuticals

Active, not recruiting

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Juvenile Psoriatic Arthritis | Enthesitis Related Arthritis

South Africa, Italy, Belgium, Russian Federation, Turkey, Germany, Spain, United States, Poland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

Psoriatic Arthritis

China
Novartis Pharmaceuticals

Completed

Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study

Psoriatic Arthritis | Axial Spondyloarthritis

Spain
Novartis Pharmaceuticals

Completed

Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

Juvenile Psoriatic Arthritis | Enthesitis-related Arthritis

South Africa, Italy, Belgium, Russian Federation, Turkey, Germany, United Kingdom, United States, Spain, Poland
Novartis Pharmaceuticals

Completed

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (ASLeap)

Ankylosing Spondylitis

United States
Novartis Pharmaceuticals

Completed

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS)

Psoriatic Arthritis

Germany, Netherlands, Spain, Argentina, Belgium, Colombia, Italy, United States, United Kingdom, Ireland, France, Mexico, Canada, Austria, Czechia, Hungary, Norway
Novartis Pharmaceuticals

Completed

Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM)

Ankylosing Spondylitis

Germany
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Psoriatic Arthritis

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES)

Psoriatic Arthritis | Enthesitis | Axial Spondyloarthritis

Germany, Spain, United Kingdom, Greece, Bulgaria, Italy, Czechia, Slovakia
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis (EXCEED 1)

Psoriatic Arthritis

Spain, United Kingdom, Estonia, Hungary, India, Italy, Germany, Israel, United States, Australia, Greece, Bulgaria, Lithuania, Korea, Republic of, Portugal, Russian Federation, Netherlands, France, Czechia, Canada, Poland, Slovakia, Denmar... and more
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

Ankylosing Spondyloarthritis

United Kingdom, Korea, Republic of, China, Czechia
Novartis Pharmaceuticals

Completed

Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement (MAXIMISE)

Axial Psoratic Arthritis

Belgium, Israel, Spain, Switzerland, Greece, Italy, Bulgaria, Germany, Hungary, Estonia, United Kingdom, Poland, France, Czechia, Russian Federation, Romania, Ireland, Finland
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

Psoriatic Arthritis

United States, United Kingdom, India, Austria, Denmark, Netherlands, Spain, Germany, Thailand, Israel, Argentina, Greece, Philippines, Latvia, Italy, Guatemala, Russian Federation, Hungary, Ireland, Vietnam, Czechia, Canada, Sweden, M... and more
University of Liverpool
Novartis

Completed

Effect of Secukinumab in the Treatment of Psoriatic Arthritis (SATURN)

Psoriatic Arthritis

United Kingdom
Novartis Pharmaceuticals

Completed

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)

Anklyosing Spondylitis

Germany, Austria, Spain, Switzerland, United Kingdom, United States, Singapore, Russian Federation, Netherlands, Italy, Finland, Czechia, Canada
University of Erlangen-Nürnberg Medical School

Completed

Psoriasis-Arthritis & Bone Program (PSARTROS)

Psoriasis | Psoriatic Arthritis

Germany
Novartis Pharmaceuticals

Completed

Extension in AS: Sustainability of Benefits, Safety and Tolerability (MEASURE 1 ext)

Spondylitis, Ankylosing

Belgium, Germany, Netherlands, France, United States, Bulgaria, Italy, Mexico, Russian Federation, Peru, United Kingdom, Turkey, Canada, Taiwan
Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis (FUTURE 4)

Arthritis, Psoriatic

United States, Italy, Germany, Australia, Belgium, Poland, Bulgaria, Russian Federation, Czechia, Canada, France, Sweden, United Kingdom
Novartis Pharmaceuticals

Completed

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)

Psoriatic Arthritis

United Kingdom, Belgium, Germany, Thailand, Israel, United States, Philippines, Singapore, Italy, Argentina, Russian Federation, Bulgaria, Czechia, Australia, Canada, Poland, Brazil, Slovakia
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)

Spondylitis, Ankylosing

Germany, Austria, Denmark, United States, Australia, Netherlands, Poland, Italy, Bulgaria, Spain, Russian Federation, United Kingdom, Greece, Czechia, Canada, Norway, Slovakia, Switzerland, Finland
Novartis Pharmaceuticals

Completed

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (MEASURE 3)

Spondylitis, Ankylosing

Germany, Spain, United Kingdom, United States, Belgium, Greece, Portugal, Russian Federation, Czechia, Mexico
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents (REASSURE)

Rheumatoid Arthritis

Colombia, United States, Belgium, Turkey, Thailand, Argentina, Italy, Guatemala, India, Japan, Panama, Hungary, United Kingdom, Mexico, Puerto Rico, Canada
Novartis Pharmaceuticals

Completed

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE 1)

Ankylosing Spondylitis

Germany, Belgium, Netherlands, France, United States, Bulgaria, Italy, Russian Federation, Peru, United Kingdom, Canada, Mexico, Taiwan, Turkey
Novartis Pharmaceuticals

Terminated

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. (REASSURE2)

Rheumatoid Arthritis

United States, Germany, Greece, Argentina, Brazil, Colombia, Czech Republic, Dominican Republic, Guatemala, India, Italy, Japan, Korea, Republic of, Panama, Portugal, South Africa
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) (NURTURE 1)

Rheumatoid Arthritis

Colombia, United States, Italy, Germany, Spain, France, Hungary, Bulgaria, Brazil, Czech Republic, Russian Federation, Slovakia, Canada, Mexico, Romania
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

Rheumatoid Arthritis

Hungary, Belgium, Germany, United States, Czech Republic, Korea, Republic of, Russian Federation, Taiwan, Poland, Slovakia, Japan
Novartis Pharmaceuticals

Completed

A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

Germany, United States, Belgium, Russian Federation, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

Rheumatoid Arthritis

Hungary, Italy, United States, Bulgaria, Poland, Canada, Slovakia, Puerto Rico

Search clinical trials for: cain457f

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations